Over the last few years, the Laura and John Arnold Foundation has tried to influence the national conversation over rising prescription drug costs by funding pilot projects and academic research.
Despite increasing scrutiny of their motives, the couple generally lets their work do the talking. But last Friday, John Arnold made a rare appearance before a select group of mostly drug company employees, as well as a few academics and patient advocates.
The occasion was to discuss ways to improve clinical trial transparency, one of many issues that plague the pharmaceutical industry. The session was hosted by Jennifer Miller, a Yale University professor who runs Bioethics International, a nonprofit that receives backing from the foundation.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
